trial · primary record
Cabozantinib
Osteosarcoma
| Phase | Phase 2 |
|---|---|
| Status | TERMINATED |
| Sponsor | Unknown |
| Enrolment | 10 |
| Primary completion | 2026-02-27 |
| Primary endpoint | Progression-free Survival (PFS) Assessed by Blinded Independent Radiology Committee (BIRC) |
| Registry ID | NCT06341712 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-29T14:34:22.383Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT06341712
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- CABOZANTINIB · approval
- Cabozantinib · compound